These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 23495860)

  • 1. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute care among asthma patients using budesonide/formoterol or fluticasone propionate/salmeterol.
    Blais L; Beauchesne MF; Forget A
    Respir Med; 2009 Feb; 103(2):237-43. PubMed ID: 18930647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study.
    Kuna P
    Clin Drug Investig; 2010; 30(9):565-79. PubMed ID: 20593912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.
    Tunceli O; Williams SA; Kern DM; Elhefni H; Pethick N; Wessman C; Zhou S; Trudo F
    J Allergy Clin Immunol Pract; 2014; 2(6):719-26. PubMed ID: 25439363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
    Aalbers R; Backer V; Kava TT; Omenaas ER; Sandström T; Jorup C; Welte T
    Curr Med Res Opin; 2004; 20(2):225-40. PubMed ID: 15006018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
    Nannini L; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.
    Nannini LJ; Poole P; Milan SJ; Kesterton A
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD006826. PubMed ID: 23990350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
    Vogelmeier C; Naya I; Ekelund J
    Clin Drug Investig; 2012 Jul; 32(7):439-49. PubMed ID: 22607479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.
    Akamatsu T; Shirai T; Kato M; Yasui H; Hashimoto D; Fujisawa T; Tsuchiya T; Inui N; Suda T; Chida K
    Pulm Pharmacol Ther; 2014 Feb; 27(1):52-6. PubMed ID: 23583566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
    Janson C; Larsson K; Lisspers KH; Ställberg B; Stratelis G; Goike H; Jörgensen L; Johansson G
    BMJ; 2013 May; 346():f3306. PubMed ID: 23719639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Nannini LJ; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD006829. PubMed ID: 22972099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.